Investment Rating - The report maintains a "Buy" rating for Innovent Biologics [12]. Core Insights - The first-generation immune checkpoint inhibitors (IO therapies) are facing patent expirations between 2028 and 2032, creating a significant demand for second-generation IO therapies, which are projected to have a market size of approximately $200 billion [4][7]. - The first-generation PD-1 inhibitors, represented by Keytruda (pembrolizumab) and Opdivo (nivolumab), achieved global sales of $46 billion in 2023, with an expected increase to $52.5 billion in 2024, reflecting a year-on-year growth of 18% [7][20]. - IBI363, developed by Innovent Biologics, demonstrates Best-in-Class potential through its unique PD-1 monoclonal antibody/IL-2 fusion design, showing promising results in treating both hot and cold tumors [9][68]. Summary by Sections Second-Generation IO Therapies - The second-generation IO market is categorized into three segments: replacement of first-generation IO, addressing resistance in first-generation IO, and targeting cold tumors, with a total potential market size estimated at $200 billion [7][49]. - The report highlights the urgency for multinational corporations (MNCs) to secure their positions in the next-generation cornerstone cancer therapies as first-generation patents expire [4][7]. IBI363 Molecular Design - IBI363 employs a unique PD-1 monoclonal antibody and IL-2 fusion design, achieving dual activation of effector T cells by "releasing the brake" and "pressing the accelerator" [8][56]. - The drug features a globally innovative α-biased IL-2 design, which reduces peripheral toxicity while enhancing therapeutic efficacy [57][62]. Clinical Performance of IBI363 - IBI363 has shown significant clinical benefits in various tumor types, including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC), with promising long-term overall survival (OS) trends [9][68]. - In clinical trials, IBI363 demonstrated a confirmed objective response rate (ORR) of 36.7% and a disease control rate (DCR) of 90% in squamous NSCLC patients, with a median progression-free survival (mPFS) of 9.3 months [69].

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect in the healthcare sector has shown significant growth, with a year-to-date increase of 49.37% [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Healthcare Composite Index (930965) rose by 0.85%, reaching 3051.69 points, with a trading volume of 18.538 billion yuan [1]. - Over the past month, the index has increased by 9.40%, and over the last three months, it has risen by 15.29% [1]. Group 2: Index Composition - The index comprises 50 liquid and large-cap healthcare companies listed under the Hong Kong Stock Connect, reflecting the overall performance of these securities [1]. - The index was established on November 14, 2014, with a base point of 3000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: - Innovent Biologics (9.96%) - WuXi Biologics (9.13%) - BeiGene (8.86%) - CanSino Biologics (5.83%) - CSPC Pharmaceutical Group (5.6%) - China Biologic Products (5.26%) - JD Health (4.73%) - 3SBio (4.07%) - Hansoh Pharmaceutical (3.15%) - Zai Lab (2.69%) [1]. Group 4: Market and Sector Allocation - The index's holdings are entirely composed of securities listed on the Hong Kong Stock Exchange, with a 100% allocation to the healthcare sector [1].

Core Viewpoint - The Hang Seng Healthcare Index has shown strong performance, with significant gains in constituent stocks, indicating a positive trend in the healthcare sector [1][3]. Group 1: Market Performance - As of July 2, 2025, the Hang Seng Healthcare Index rose by 1.75%, with notable increases in stocks such as SiPai Health (+46.34%) and HuaHao ZhongTian Pharma-B (+22.68%) [1]. - The Hang Seng Healthcare ETF (159557) experienced a 0.62% increase, marking its third consecutive rise [1]. - The trading volume for the Hang Seng Healthcare ETF was active, with a turnover of 43.37 million yuan and a turnover rate of 14.33% [3]. Group 2: Fund Performance - The Hang Seng Healthcare ETF has seen a significant increase in scale, growing by 5.73 million yuan over the past two weeks, ranking first among comparable funds [3]. - The ETF's net asset value increased by 66.32% over the past year, placing it 16th out of 119 QDII equity funds, which is in the top 13.45% [3]. - The ETF has recorded a maximum monthly return of 23.84% since its inception, with an average monthly return of 7.67% during rising months [3]. Group 3: Valuation Metrics - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.1, which is at a historical low, being in the 8.88th percentile over the past three years [3]. - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.72% of the index, with notable companies including Innovent Biologics and BeiGene [4][6]. Group 4: Industry Outlook - Recent measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, focusing on R&D support and inclusion in insurance directories [6]. - Analysts from Huayuan Securities and Xiangcai Securities express optimism for the innovative drug sector, anticipating a shift from capital-driven growth to profit-driven growth in 2025 [7].

Core Viewpoint - The recent adjustments in the commercial health insurance drug directory signify an important step for the commercial health insurance market's entry, enhancing its role in the multi-tiered medical security system in China [4][5]. Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) rose by 2.32% as of July 2, 2025, with notable increases in constituent stocks such as SiPai Health (00314) up 43.53% and Huahao Zhongtian Pharmaceutical-B (02563) up 41.04% [3]. - The Hang Seng Healthcare ETF (513060) increased by 0.87%, marking its third consecutive rise, with a latest price of 0.58 yuan [3]. - Over the past week, the Hang Seng Healthcare ETF has accumulated a rise of 0.53% [3]. Group 2: Liquidity and Trading Volume - The Hang Seng Healthcare ETF had a turnover rate of 2.96% during the trading session, with a transaction volume of 247 million yuan [3]. - The average daily trading volume for the ETF over the past month was 2.139 billion yuan, ranking it first among comparable funds [3]. Group 3: Fund Performance and Metrics - The latest scale of the Hang Seng Healthcare ETF reached 7.997 billion yuan, placing it in the top third among comparable funds [4]. - The ETF's financing buy amount was 94.5905 million yuan, with a financing balance of 292 million yuan [4]. - The net value of the ETF has increased by 15.65% over the past two years, with a maximum single-month return of 28.34% since inception [4]. Group 4: Risk and Return Analysis - As of July 1, 2025, the ETF's relative drawdown against the benchmark was 0.45%, the smallest among comparable funds, with a recovery period of 43 days [5]. - The management fee for the ETF is 0.50%, and the custody fee is 0.15% [5]. - The tracking error for the ETF over the past year was 0.070%, the highest tracking precision among comparable funds [5]. Group 5: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Healthcare Index is 27.1, indicating a valuation below 91.12% of the time over the past three years, suggesting a historical low [5]. - The top ten weighted stocks in the HSHCI account for 57.72% of the index, including companies like Innovent Biologics (01801) and BeiGene (06160) [5].

Core Insights - The core investment theme for the first half of 2025 revolves around opportunities in the Hong Kong stock market and the recovery of the pharmaceutical sector [1][2][3] Fund Performance - The top-performing fund for the first half of 2025 is the Huatai-PineBridge Hong Kong Advantage Select A, achieving a return of 85.64% [2][3] - Other notable funds include CITIC Construction Investment North Exchange Select Two-Year Open A with a return of 82.45% and Great Wall Pharmaceutical Industry Select A with a return of 75.18% [2][3] - Among the top ten funds, six are from CITIC Construction Investment, Huaxia, and Great Wall, focusing on the North Exchange or pharmaceutical sectors, all exceeding a 66% return [3] Pharmaceutical Sector Highlights - The pharmaceutical and biotechnology sectors have shown strong performance, with various funds achieving significant returns, such as the Bank of China Hong Kong Stock Connect Pharmaceutical A at 70.08% and Ping An Pharmaceutical Select A at 58.80% [4][5] - The overall pharmaceutical index has risen by 26.74% year-to-date, with the innovative drug sector outperforming, showing a year-to-date increase of 24.83% [5][6] Market Dynamics - The Hong Kong stock market, particularly in the innovative drug sector, has become a focal point for investors, with the Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of over 60% [7][9] - The innovative drug sector is expected to continue attracting investment due to favorable policies and commercial acceleration, with significant transactions in the sector reaching $45.5 billion in the first five months of the year [6][9] Future Outlook - The investment strategy for the second half of 2025 is anticipated to focus on growth sectors, particularly innovative drugs, with three main investment themes identified: commercialization in the domestic medical insurance market, international licensing of domestic innovative drugs, and capitalizing on industry cycles and valuation opportunities [4][5] - The overall valuation of the innovative drug sector remains reasonable, providing potential opportunities for investment despite previous market corrections [5][9]

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the healthcare sector, including JD Health, WuXi AppTec, and Innovent Biologics, among others [1]. Core Insights - The innovative drug revenue for the companies is expected to exceed 10 billion yuan in 2025, with innovative drugs projected to account for over 80% of total revenue [22]. - The oncology pipeline leadership is expanding, with core products like Ameitini expected to reach peak sales of 8 billion yuan [22]. - The ADC (Antibody-Drug Conjugate) market is projected to reach $64.7 billion by 2030, with a CAGR of 30% [17]. Summary by Sections Company Ratings - Companies rated as "Outperform" include JD Health, WuXi AppTec, Innovent Biologics, and BeiGene [1]. - Neutral rating is assigned to China National Pharmaceutical Group [1]. Market Trends - The report highlights a strong performance in the online pharmacy sector, driven by chronic disease drugs and innovative weight-loss medications [34]. - JD Health's revenue growth accelerated to 25.5% YoY in Q1 2025, indicating a robust market position [34]. Pipeline and Product Development - The report emphasizes the importance of ADC technology platforms, with several companies establishing global partnerships valued over $6 billion [22]. - Upcoming catalysts include approvals for various ADC products and significant clinical data releases expected in 2025 [34]. Financial Projections - The innovative drug industry chain is expected to grow by over 15% YoY, with high-margin polypeptide business projected to maintain over 60% growth [29]. - Companies like BeiGene are expected to see peak sales in their hematological oncology segment exceed $8 billion [24].

Group 1: Market Overview - In the first half of 2025, global capital markets experienced significant fluctuations, with different markets showing various highlights. The US stock market saw the Dow Jones increase by 3.64%, the Nasdaq 100 by 7.93%, and the S&P 500 by 5.5% [1] - The Hong Kong stock market outperformed, with the Hang Seng Index, Hang Seng Tech Index, and Hang Seng China Enterprises Index rising by 20%, 18.68%, and 19.05% respectively, indicating a strong capital inflow into Hong Kong stocks [1] - A-shares showed a structural market trend, with small-cap stocks outperforming larger indices, as evidenced by the Shanghai Stock Exchange 50 Index rising by only 1.01% while the CSI 2000 Index increased by 15.24% [1] Group 2: Fund Performance - As of June 30, 2025, there were 22,090 open-end funds (excluding money market and QDII funds) in the domestic market, with 86.26% of them generating positive returns in the first half of the year [2] - Among QDII funds, 87.15% achieved positive returns, with 13.15% of these funds yielding returns of 20% or more [2] - A total of 988 open-end funds outperformed the Hang Seng Index, representing 4.34% of all non-money market funds, indicating a concentration of high-quality products [2] Group 3: Top Performing Funds - The top 20 open-end funds in terms of performance for the first half of 2025 had returns ranging from 82.45% to 56.70%, significantly outperforming major indices [3] - The majority of these top-performing funds were heavily invested in the healthcare sector, with 11 out of the 20 funds focusing on the pharmaceutical and health industries [4][5] - In the QDII category, the top 10 funds had returns between 86% and 46.71%, with all funds heavily weighted in pharmaceutical stocks [9][10] Group 4: Sector Analysis - The healthcare sector, particularly innovative pharmaceuticals, showed remarkable performance, with the A-share innovative drug concept rising by 26.1% and the Hang Seng Biotechnology Index increasing by 50.65% [13] - The strong performance of the pharmaceutical sector has led to a significant recovery for funds that were previously underperforming in this category, marking a notable turnaround in the market [13]

Core Insights - The total trading volume of non-monetary ETFs reached 209.623 billion yuan, with 42 ETFs exceeding 1 billion yuan in trading volume [1] - The Short-term Bond ETF, Shanghai Company Bond ETF, and Government Financial Bond ETF led the market in trading volume, with respective volumes of 13.515 billion, 13.019 billion, and 9.858 billion yuan [1] - The Hong Kong Stock Connect 50 ETF, Hang Seng Hong Kong Stock Connect ETF, and Benchmark National Bond ETF had the highest turnover rates, reaching 1067.75%, 626.30%, and 362.76% respectively [1] Trading Volume and Performance - The Short-term Bond ETF (511360.SH) has a latest share size of 437 million, closely tracking the China Bond Short-term Index [1] - The Shanghai Company Bond ETF (511070.SH) has a latest share size of 214 million and tracks the Shanghai Market Maker Company Bond Index [2] - The Hong Kong Stock Connect 100 ETF (159788.SZ) has a latest share size of 100 million and tracks the Hong Kong Stock Connect China 100 Index, with a significant trading volume increase of 8127.12% [3] Turnover Rates - The Hong Kong Stock Connect 50 ETF and Hang Seng Hong Kong Stock Connect ETF have the highest turnover rates at 1067.75% and 626.30% respectively [7] - The Benchmark National Bond ETF also shows a high turnover rate of 362.76% [7] Volatility and Price Movement - The CSI 300 ETF (510320.SH) experienced a price increase of 0.19% with a volatility of 9.54% [8] - The Hong Kong Stock Connect 100 ETF showed a price increase of 1.76% with a volatility of 8.13% [11] - The Innovative Drug ETF (159748.SZ) had a price increase of 5.88% and a volatility of 7.94% [9]

Core Viewpoint - The recent policy measures introduced by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs in China, addressing key challenges in the industry from research to market access [1][4]. Group 1: Policy Measures - The new measures include 16 targeted initiatives designed to tackle the difficulties in research, payment, and hospital access for innovative drugs, which are seen as a significant boost for the domestic pharmaceutical innovation engine [1][2]. - The policy encourages commercial health insurance to establish investment funds for innovative drug research, addressing long-term funding shortages [2]. Group 2: Research and Development - The measures allow for the opening of national unified medical insurance data, providing pharmaceutical companies and research institutions with access to critical data resources, which will help in efficiently identifying research targets and optimizing development pipelines [1][3]. - Companies can now apply for "point-to-point" policy guidance from the insurance department as soon as their new drug application is accepted, clarifying key elements for market access [2]. Group 3: Payment and Market Access - The introduction of a "commercial health insurance innovative drug directory" provides a new pathway for high-value innovative drugs that may not fit into basic medical insurance coverage, allowing for price confidentiality and exemption from certain regulations [3]. - The measures state that medical institutions cannot restrict the allocation of innovative drugs based on "drug proportion" or the number of drugs in the directory, enhancing the chances for high-value innovative drugs to enter hospitals [3]. Group 4: Market Outlook - The innovative drug sector is expected to continue its upward trend, driven by a recognition of the commercial model and the long-term value of leading companies, with a positive outlook for the industry’s fundamentals [5][7]. - The current market environment is characterized by a revaluation of research assets, with a focus on data asset pricing rather than business development (BD) pricing, indicating that high-quality research data will attract reasonable market valuations [6]. Group 5: Company Highlights - Heng Rui Medicine (恒瑞医药) is projected to achieve a revenue of 27.985 billion yuan in 2024, reflecting a 22.6% increase, with innovative drug sales expected to rise from 38.1% of total revenue in 2022 to 46.3% in 2024 [8]. - Three Life Pharmaceuticals (三生制药) has made significant strides in international collaboration, with a recent deal with Pfizer valued at up to $6.15 billion, showcasing the clinical value of its dual antibody platform [9].